Tag Archive for: Belgium biotechnology

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

Financing will be used to advance Rewind’s lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models Leuven, Belgium – 6 October 2026 – Rewind Therapeutics (“Rewind”), a biotechnology company developing small-molecule […]

© Optimum Strategic Communications.